What AC Immune SA's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 2 |
| Total trades | 0 | 7 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 7 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| June Carl Howard | Director | Jun 11 | Grant / award · A | +16,568 | — | — | 67,556 |
| Buetler Monika | Director | Jun 11 | Grant / award · A | +17,751 | — | — | 71,656 |
| Aguiar-lucander Renee | Director | Jun 11 | Grant / award · A | +16,568 | — | — | 51,136 |
| Zuegel Martin | Interim CEO | Jun 11 | Grant / award · A | +33,136 | — | — | 71,408 |
| Twyman Roy Ervin | Director | Jun 11 | Grant / award · A | +16,568 | — | — | 92,556 |
| Pfeifer Andrea | Chief Executive Officer | May 15 | Open-market sale · S | −10,000 | $2.79 | −$27.9K | 3,820,288 |
| Pfeifer Andrea | Chief Executive Officer | Apr 15 | Open-market sale · S | −10,000 | $3.14 | −$31.4K | 3,830,288 |
Loading...